Literature DB >> 9347943

Kinetics of nigral degeneration in a chronic model of MPTP-treated mice.

E Bezard1, S Dovero, B Bioulac, C E Gross.   

Abstract

The chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model we have developed in monkey reproduces all the cardinal features of Parkinson's disease, and, in particular the characteristic slow evolution of clinical signs. We still know little, however, of the kinetics of the nigral degeneration induced. This present study charts the progressive destruction of tyrosine hydroxylase-immunoreactive neurones in mice treated daily with low doses of MPTP for 20 days. Our results show that the neuronal death rate is initially high, subsequently decreases, and stabilizes. This new protocol thus mirrors closely the pattern of evolution assumed to be that of Parkinson's disease and should prove useful for studies on neuroprotection and compensatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347943     DOI: 10.1016/s0304-3940(97)00663-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

Review 2.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

3.  Altered pallido-pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease.

Authors:  Cristina Miguelez; Stéphanie Morin; Audrey Martinez; Michel Goillandeau; Erwan Bezard; Bernard Bioulac; Jérôme Baufreton
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

4.  Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients.

Authors:  Hua She; Qian Yang; Kennie Shepherd; Yoland Smith; Gary Miller; Claudia Testa; Zixu Mao
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

5.  Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.

Authors:  C J van der Schyf; K Castagnoli; S Palmer; L Hazelwood; N Castagnoli
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

Review 6.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

7.  Protective Role of rAAV-NDI1, Serotype 5, in an Acute MPTP Mouse Parkinson's Model.

Authors:  Jennifer Barber-Singh; Byoung Boo Seo; Akemi Matsuno-Yagi; Takao Yagi
Journal:  Parkinsons Dis       Date:  2010-12-06

Review 8.  Parkinson's disease mouse models in translational research.

Authors:  Paul M A Antony; Nico J Diederich; Rudi Balling
Journal:  Mamm Genome       Date:  2011-05-11       Impact factor: 2.957

9.  IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.

Authors:  Romina Aron Badin; Brigitte Spinnewyn; Marie-Claude Gaillard; Caroline Jan; Carole Malgorn; Nadja Van Camp; Frédéric Dollé; Martine Guillermier; Sabrina Boulet; Anne Bertrand; Marc Savasta; Michel Auguet; Emmanuel Brouillet; Pierre-Etienne Chabrier; Philippe Hantraye
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

10.  Depletion of canonical Wnt signaling components has a neuroprotective effect on midbrain dopaminergic neurons in an MPTP-induced mouse model of Parkinson's disease.

Authors:  Ting-Li Dai; Chan Zhang; Fang Peng; Xue-Yuan Niu; Ling Hu; Qiong Zhang; Ying Huang; Ling Chen; Lei Zhang; Weidong Zhu; Yu-Qiang Ding; Ning-Ning Song; Min Liao
Journal:  Exp Ther Med       Date:  2014-05-28       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.